trending Market Intelligence /marketintelligence/en/news-insights/trending/UaCx7VsCIcmNYKLioMw-NA2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Sanofi's $2.5B acquisition of I-O company Synthorx gets antitrust clearance

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform


Sanofi's $2.5B acquisition of I-O company Synthorx gets antitrust clearance

Sanofi's $2.5 billion acquisition of immuno-oncology company Synthorx Inc. received antitrust clearance.

The Paris-based drugmaker said the waiting period under the Hart-Scott-Rodino Act applicable to the deal has expired.

On Dec. 23, 2019, Sanofi started a tender offer to acquire all of Synthorx's shares at $68 each.

La Jolla, Calif.-based Synthorx is developing therapies intended to treat cancer and autoimmune disorders through its proprietary technology. The company's lead asset, THOR-707, is being evaluated as a potential treatment of multiple solid tumor types as a stand-alone therapy and in combination with immune checkpoint inhibitors.